nach oben

Current Osteoporosis Reports

Erschienen in:

01.06.2014 | Muscle and Bone (L Bonewald and M Harrick, Section Editors)

Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?

verfasst von: Christian M. Girgis, Nancy Mokbel, Douglas J. DiGirolamo

Erschienen in: Current Osteoporosis Reports | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Musculoskeletal diseases are highly prevalent with staggering annual health care costs across the globe. The combined wasting of muscle (sarcopenia) and bone (osteoporosis)—both in normal aging and pathologic states—can lead to vastly compounded risk for fracture in patients. Until now, our therapeutic approach to the prevention of such fractures has focused solely on bone, but our increasing understanding of the interconnected biology of muscle and bone has begun to shift our treatment paradigm for musculoskeletal disease. Targeting pathways that centrally regulate both bone and muscle (eg, GH/IGF-1, sex steroids, etc.) and newly emerging pathways that might facilitate communication between these 2 tissues (eg, activin/myostatin) might allow a greater therapeutic benefit and/or previously unanticipated means by which to treat these frail patients and prevent fracture. In this review, we will discuss a number of therapies currently under development that aim to treat musculoskeletal disease in precisely such a holistic fashion.

Australian Bureau of Statistics. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/cat/4823.0.55.001. 2005. Accessed Dec 2013.

Connelly LB, Woolf A, Brooks P. Cost-effectiveness of interventions for musculoskeletal conditions. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries, 2nd edn. Washington, DC: Oxford University Press and World Bank; 2006. p. 963–8.

Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–33. doi:10.1007/s00198-006-0172-4.PubMed

4.••

Bonewald LF, Kiel DP, Clemens TL, Esser K, Orwoll ES, O'Keefe RJ, et al. Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2013;28(9):1857–65. doi:10.1002/jbmr.1980. This perspective article summarizes an ASBMR workshop on bone-muscle interactions, outlines current concepts in the field, and research questions to stmulate potential therapeutic strategies for musculoskeletal disorders.PubMed

Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, et al. Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int. 2012;23(7):1839–48. doi:10.1007/s00198-012-1913-1.PubMed

Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.PubMed

Scott D, Hayes A, Sanders KM, Aitken D, Ebeling PR, Jones G. Operational definitions of sarcopenia and their associations with 5-year changes in falls risk in community-dwelling middle-aged and older adults. Osteoporos Int. 2014;25(1):187–93. doi:10.1007/s00198-013-2431-5.PubMed

8.••

DiGirolamo DJ, Kiel DP, Esser KA. Bone and skeletal muscle: neighbors with close ties. J Bone Miner Res. 2013;28(7):1509–18. doi:10.1002/jbmr.1969. This perspective article reviews bone-muscle interactions throughout development and aging and highlights the predominant nature of muscle in this relationship.

Schoenwolf GC, Bleyl SB, Brauer PR, Francis-West PH. Chapter 8: Development of the musculoskeletal system. Larsen's human embryology 4th edition. Philadelphia: Churchill Livingstone/Elsevier; 2009.

10.•

Karasik D, Kiel DP. Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone. 2010;46(5):1226–37. doi:10.1016/j.bone.2010.01.382. This review covers genetic aspects of bone-muscle interactions, providing valuable insight in the common genetic etiology of osteoporosis and sarcopenia.PubMed

11.

Kahn J, Shwartz Y, Blitz E, Krief S, Sharir A, Breitel DA, et al. Muscle contraction is necessary to maintain joint progenitor cell fate. Dev Cell. 2009;16(5):734–43. doi:10.1016/j.devcel.2009.04.013.PubMed

12.

Nowlan NC, Bourdon C, Dumas G, Tajbakhsh S, Prendergast PJ, Murphy P. Developing bones are differentially affected by compromised skeletal muscle formation. Bone. 2010;46(5):1275–85. doi:10.1016/j.bone.2009.11.026.PubMedCentralPubMed

13.

Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 2000;20(1):71–4.PubMed

14.

Shaw NJ, White CP, Fraser WD, Rosenbloom L. Osteopenia in cerebral palsy. Arch Dis Child. 1994;71(3):235–8.PubMedCentralPubMed

15.

Sharir A, Stern T, Rot C, Shahar R, Zelzer E. Muscle force regulates bone shaping for optimal load-bearing capacity during embryogenesis. Development. 2011;138(15):3247–59. doi:10.1242/dev.063768.PubMed

16.

Slizewski A, Schonau E, Shaw C, Harvati K. Muscle area estimation from cortical bone. Anat Rec. 2013. doi:10.1002/ar.22788.

17.

Szulc P, Beck TJ, Marchand F, Delmas PD. Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men—the MINOS study. J Bone Miner Res. 2005;20(5):721–9. doi:10.1359/JBMR.041230.PubMed

18.

Rikkonen T, Sirola J, Salovaara K, Tuppurainen M, Jurvelin JS, Honkanen R, et al. Muscle strength and body composition are clinical indicators of osteoporosis. Calcif Tissue Int. 2012;91(2):131–8. doi:10.1007/s00223-012-9618-1.PubMed

19.

Keyak JH, Koyama AK, LeBlanc A, Lu Y, Lang TF. Reduction in proximal femoral strength due to long-duration spaceflight. Bone. 2009;44(3):449–53. doi:10.1016/j.bone.2008.11.014.PubMed

20.••

Lebrasseur NK, Achenbach SJ, Melton III LJ, Amin S, Khosla S. Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men. J Bone Miner Res. 2012;27(10):2159–69. doi:10.1002/jbmr.1666. This observational study of ~ 590 patients reported an association between appendicular muscle mass, bone cortical thickness at remote sites, and serum insulin-like growth factor (IGF) binding protein-2 (IGFBP-2) levels. This further supports the integrated nature of bone-muscle cross-talk.PubMedCentralPubMed

21.

Harry LE, Sandison A, Paleolog EM, Hansen U, Pearse MF, Nanchahal J. Comparison of the healing of open tibial fractures covered with either muscle or fasciocutaneous tissue in a murine model. J Orthop Res. 2008;26(9):1238–44. doi:10.1002/jor.20649.PubMed

22.

Gopal S, Majumder S, Batchelor AG, Knight SL, De Boer P, Smith RM. Fix and flap: the radical orthopaedic and plastic treatment of severe open fractures of the tibia. J Bone Joint Surg (Br). 2000;82(7):959–66.

23.

Reverte MM, Dimitriou R, Kanakaris NK, Giannoudis PV. What is the effect of compartment syndrome and fasciotomies on fracture healing in tibial fractures? Injury. 2011;42(12):1402–7. doi:10.1016/j.injury.2011.09.007.PubMed

24.

Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010;10(1):56–63.PubMedCentralPubMed

25.

Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–65. doi:10.1038/nrendo.2012.49.PubMed

26.

Cianferotti L, Brandi ML. Muscle-bone interactions: basic and clinical aspects. Endocrine. 2013. doi:10.1007/s12020-013-0026-8.PubMed

27.••

DiGirolamo DJ, Clemens TL, Kousteni S. The skeleton as an endocrine organ. Nat Rev Rheumatol. 2012;8(11):674–83. doi:10.1038/nrrheum.2012.157. This review presents bone as an endocrine organ based on the discovery of unique ‘osteokines’ with effects in glucose and energy homeostasis.PubMed

28.

Christoforidis A, Maniadaki I, Stanhope R. Growth hormone / insulin-like growth factor-1 axis during puberty. Pediatr Endocrinol Rev. 2005;3(1):5–10.PubMed

29.

Perrini S, Carreira MC, Conserva A, Laviola L, Giorgino F. Metabolic implications of growth hormone therapy. J Endocrinol Invest. 2008;31(9 Suppl):79–84.PubMed

30.

Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol. 2010;205(3):201–10. doi:10.1677/JOE-09-0431.PubMed

31.••

Mavalli MD, DiGirolamo DJ, Fan Y, Riddle RC, Campbell KS, van Groen T, et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest. 2010;120(11):4007–20. doi:10.1172/JCI42447. This study delineates specific effects of GH signaling in muscle via the generation of 2 different mouse models. Effects of GH in muscle development depend on IGF-1, whilst effects on insulin sensitivity are IGF-1-independent.PubMedCentralPubMed

32.

Rojas Vega S, Knicker A, Hollmann W, Bloch W, Struder HK. Effect of resistance exercise on serum levels of growth factors in humans. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2010;42(13):982–6. doi:10.1055/s-0030-1267950.

33.

Jennische E, Hansson HA. Regenerating skeletal muscle cells express insulin-like growth factor I. Acta Physiol Scand. 1987;130(2):327–32. doi:10.1111/j.1748-1716.1987.tb08144.x.PubMed

34.

Miller WL, Eberhardt NL. Structure and evolution of the growth hormone gene family. Endocr Rev. 1983;4(2):97–130. doi:10.1210/edrv-4-2-97.PubMed

35.

Carter-Su C, Schwartz J, Smit LS. Molecular mechanism of growth hormone action. Annu Rev Physiol. 1996;58:187–207. doi:10.1146/annurev.ph.58.030196.001155.PubMed

36.

Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. doi:10.1210/er.2007-0036.PubMedCentralPubMed

37.

Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology. 1997;138(9):3849–58. doi:10.1210/endo.138.9.5370.PubMed

38.

Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology. 1988;122(1):254–60. doi:10.1210/endo-122-1-254.PubMed

39.

DiGirolamo DJ, Mukherjee A, Fulzele K, Gan Y, Cao X, Frank SJ, et al. Mode of growth hormone action in osteoblasts. J Biol Chem. 2007;282(43):31666–74. doi:10.1074/jbc.M705219200.PubMed

40.

Laron Z. Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity? Mech Ageing Dev. 2005;126(2):305–7. doi:10.1016/j.mad.2004.08.022.PubMed

41.

Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, et al. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int. 2008;19(2):221–6. doi:10.1007/s00198-007-0440-y.PubMed

42.

Leger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008;11(1):163–75B. doi:10.1089/rej.2007.0588.PubMed

43.

Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res. 1995;10(12):1844–52. doi:10.1002/jbmr.5650101203.PubMed

44.

Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1–6. doi:10.1056/NEJM199007053230101.PubMed

45.

Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement. Front Endocrinol. 2013;4:64. doi:10.3389/fendo.2013.00064.

46.

Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–15.PubMed

47.

Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996;124(8):708–16.PubMed

48.

Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288(18):2282–92.PubMed

49.

Berryman DE, Christiansen JS, Johannsson G, Thorner MO, Kopchick JJ. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res. 2008;18(6):455–71. doi:10.1016/j.ghir.2008.05.005.PubMedCentralPubMed

50.

Human Body Size and the Laws of Scaling: Physiological, Performance, Growth, Longevity and Ecological Ramifications. In: Samaras T, editor. New York: Nova Science Publishers; 2007.

51.

Melmed GY, Devlin SM, Vlotides G, Dhall D, Ross S, Yu R, et al. Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis. Clin Gastroenterol Hepatol. 2008;6(3):360–3. doi:10.1016/j.cgh.2007.12.017.PubMedCentralPubMed

52.

Holt LJ, Turner N, Mokbel N, Trefely S, Kanzleiter T, Kaplan W, et al. Grb10 regulates the development of fiber number in skeletal muscle. FASEB. 2012;26(9):3658–69. doi:10.1096/fj.11-199349.

53.

Solomon AM, Bouloux PM. Modifying muscle mass—the endocrine perspective. J Endocrinol. 2006;191(2):349–60. doi:10.1677/joe.1.06837.PubMed

54.

Veldhuis JD, Patrie JM, Frick K, Weltman JY, Weltman AL. Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. Eur J Endocrinol. 2005;153(5):669–77. doi:10.1530/eje.1.02019.PubMed

55.

Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell Jr FE, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601–11.PubMedCentralPubMed

56.

White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94(4):1198–206. doi:10.1210/jc.2008-0632.PubMed

57.

Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev. 2004;25(3):389–425. doi:10.1210/er.2003-0003.PubMed

58.

Chen Y, Zajac JD, MacLean HE. Androgen regulation of satellite cell function. J Endocrinol. 2005;186(1):21–31. doi:10.1677/joe.1.05976.PubMed

59.••

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi:10.1210/jc.2009-2354. These guidelines published by the Endocrine Society outline reccomendations for testing and treating androgen deficiency.PubMed

60.

Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2(3):146–59. doi:10.1038/ncpendmet0120.PubMedCentralPubMed

61.

Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91(10):3908–15. doi:10.1210/jc.2006-0173.PubMed

62.

Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91(6):2011–6. doi:10.1210/jc.2006-0036.PubMed

63.

Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63(3):280–93. doi:10.1111/j.1365-2265.2005.02339.x.

64.

Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50. doi:10.1210/jc.2009-1251.PubMed

65.•

Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414–24. doi:10.1038/nrendo.2013.73. This review summarizes benefits of testosterone therapy, its indications and risks in older men, particularly relating to cardiovascular disease, prostate conditions, and erythrocytosis.PubMed

66.

Testosterone and aging: clinical research directions. Institute of Medicine TNAP. In: Liverman CT, Blazer, DG, editors. Washington, D.C.: National, Academies Press; 2004.

67.•

Zhang X, Sui Z. Deciphering the selective androgen receptor modulators paradigm. Expert Opin Drug Discov. 2013;8(2):191–218. doi:10.1517/17460441.2013.741582. This review covers pharmacologic aspects in the development of SARMs and summarizes preclinical and clinical data.PubMed

68.

Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(12):3597–617. doi:10.1021/jm900280m.PubMed

69.

Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachex Sarcopenia Muscle. 2011;2(3):153–61. doi:10.1007/s13539-011-0034-6.

70.•

Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45. doi:10.1016/S1470-2045(13)70055-X. This clinical trial of enobosarm, a nonsteroidal SARM, showed significant increases in lean body mass but no effect in bone mineral density in patients with cancer cachexia. A phase 3 trial is currently underway.PubMed

71.

Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95. doi:10.1093/gerona/gls078.PubMed

72.•

Papanicolaou DA, Ather SN, Zhu H, Zhou Y, Lutkiewicz J, Scott BB, et al. A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging. 2013;17(6):533–43. doi:10.1007/s12603-013-0335-x. The steroidal SARM, MK-0773, resulted in significant increases in lean body mass in frail elderly women but this did not translate to improvements in muscle strength.PubMed

73.•

Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE. The roles of Vitamin D in skeletal muscle: form, function, and metabolism. Endocr Rev. 2013;34:33–83. doi:10.1210/er.2012-1012. This review summarizes effects of vitamin D in skeletal muscle from animal, cell and human studies.PubMed

74.

Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology. 1999;140(11):4982–7.PubMed

75.

Schubert L, DeLuca HF. Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch Biochem Biophys. 2010;500(2):157–61. doi:10.1016/j.abb.2010.05.029.PubMed

76.•

Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys. 2012;523(1):123–33. doi:10.1016/j.abb.2012.04.001. This article examines the tissue distribution of VDR, including organs where its presence is controversial such as liver and skeletal muscle.PubMed

77.

Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest. 2012;122(5):1803–15. doi:10.1172/JCI45890.PubMedCentralPubMed

78.

Yamamoto Y, Yoshizawa T, Fukuda T, Shirode-Fukuda Y, Yu T, Sekine K, et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology. 2013;154(3):1008–20. doi:10.1210/en.2012-1542.PubMed

79.

Lam NN, Triliana R, Sawyer RK, Atkins GJ, Morris HA, O'Loughlin PD, et al. Vitamin D receptor overexpression in osteoblasts and osteocytes prevents bone loss during vitamin D-deficiency. J Steroid Biochem Mol Biol. 2014. doi:10.1016/j.jsbmb.2014.01.002.PubMed

80.

Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology. 2003;144(12):5138–44. doi:10.1210/en.2003-0502.PubMed

81.

Girgis CM, Clifton-Bligh RJ, Mokbel N, Cheng K, Gunton JE. Vitamin D signaling regulates proliferation, differentiation and myotube size in C2C12 skeletal muscle cells. Endocrinology. 2014;155(2):347–57. doi:10.1210/en.2013-1205.PubMed

82.

Lee SG, Lee YH, Kim KJ, Lee W, Kwon OH, Kim JH. Additive association of vitamin D insufficiency and sarcopenia with low femoral bone mineral density in noninstitutionalized elderly population: the Korea National Health and Nutrition Examination Surveys 2009–2010. Osteoporos Int. 2013;24(11):2789–99. doi:10.1007/s00198-013-2378-6.PubMed

83.

Snijder MB, van Schoor NM, Pluijm SM, van Dam RM, Visser M, Lips P. Vitamin D status in relation to one-year risk of recurrent falling in older men and women. J Clin Endocrinol Metab. 2006;91(8):2980–5. doi:10.1210/jc.2006-0510.PubMed

84.

Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004;19(2):265–9. doi:10.1359/jbmr.2004.19.2.265.PubMed

85.

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257–64. doi:10.1001/jama.293.18.2257.PubMed

86.

Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc. 2007;55(2):234–9. doi:10.1111/j.1532-5415.2007.01048.x.PubMed

87.

Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669–83. doi:10.1056/NEJMoa055218.PubMed

88.

Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet. 2013. doi:10.1016/S0140-6736(13)61647-5.

89.•

Ceglia L, Niramitmahapanya S, Morais MD, Rivas DA, Harris SS, Bischoff-Ferrari H, et al. A randomized study on the effect of vitamin D3 supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. J Clin Endocrinol Metab. 2013. doi:10.1210/jc.2013–2820. This RCT of 21 older women showed an increase in myonuclear VDR and muscle fiber size amongst those receiving vitamin D supplementation (4000 IU d for 4 months). However, functional parameters were unchanged, possibly due to the small sample size.

90.•

Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815–22. doi:10.1001/jama.2010.594. This well-known RCT of 2256 community-dwelling older women reported an increased risk of falls and fractures in the 3 months following vitamin D mega-supplementation (500,000 IU oral).PubMed

91.•

Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8. doi:10.1210/jc.2010-2704. This article summarizes the IOM recommendations for 25OHD target levels (50 nmol/L) and daily vitamin D doses (800 IU in adults >70years). Extra-skeletal benefits of vitamin D were reportedly “not yet compelling”.PubMedCentralPubMed

92.•

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. doi:10.1210/jc.2011-0385. In contrast to the IOM recommendations, the Endocrine society advocated a higher 25OHD target level of 75 nmol/L and daily doses of at least 1500–2000 IU in the older age-group.PubMed

93.

Korpelainen R, Keinanen-Kiukaanniemi S, Heikkinen J, Vaananen K, Korpelainen J. Effect of impact exercise on bone mineral density in elderly women with low BMD: a population-based randomized controlled 30-month intervention. Osteoporos Int. 2006;17(1):109–18. doi:10.1007/s00198-005-1924-2.PubMed

94.

Martyn-St James M, Carroll S. Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone. 2008;43(3):521–31. doi:10.1016/j.bone.2008.05.012.PubMed

95.

Winters-Stone KM, Dobek J, Nail L, Bennett JA, Leo MC, Naik A, et al. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. Breast Cancer Res Treat. 2011;127(2):447–56. doi:10.1007/s10549-011-1444-z.PubMedCentralPubMed

96.

Winters KM, Snow CM. Detraining reverses positive effects of exercise on the musculoskeletal system in premenopausal women. J Bone Miner Res. 2000;15(12):2495–503. doi:10.1359/jbmr.2000.15.12.2495.PubMed

97.

Gilsanz V, Wren TA, Sanchez M, Dorey F, Judex S, Rubin C. Low-level, high-frequency mechanical signals enhance musculoskeletal development of young women with low BMD. J Bone Miner Res. 2006;21(9):1464–74. doi:10.1359/jbmr.060612.PubMed

98.

Dudley-Javoroski S, Shields RK. Muscle and bone plasticity after spinal cord injury: review of adaptations to disuse and to electrical muscle stimulation. J Rehabil Res Dev. 2008;45(2):283–96.PubMedCentralPubMed

99.

Serrano-Urrea R, Garcia-Meseguer MJ. Malnutrition in an elderly population without cognitive impairment living in nursing homes in Spain: study of prevalence using the Mini Nutritional Assessment test. Gerontology. 2013;59(6):490–8. doi:10.1159/000351763.PubMed

100.

Berner LA, Becker G, Wise M, Doi J. Characterization of dietary protein among older adults in the United States: amount, animal sources, and meal patterns. J Acad Nutr Diet. 2013;113(6):809–15. doi:10.1016/j.jand.2013.01.014.PubMed

101.

Houston DK, Nicklas BJ, Ding J, Harris TB, Tylavsky FA, Newman AB, et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Clin Nutr. 2008;87(1):150–5.PubMed

102.

Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care. 2009;12(1):86–90. doi:10.1097/MCO.0b013e32831cef8b.PubMedCentralPubMed

103.

Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev. 2009(2):CD003288. doi:10.1002/14651858.CD003288.pub3.

104.

Miller CT, Fraser SF, Levinger I, Straznicky NE, Dixon JB, Reynolds J, et al. The effects of exercise training in addition to energy restriction on functional capacities and body composition in obese adults during weight loss: a systematic review. PLoS One. 2013;8(11):e81692. doi:10.1371/journal.pone.0081692.PubMedCentralPubMed

105.

Buehring B, Binkley N. Myostatin - the holy grail for muscle, bone, and fat? Curr Osteoporos Rep. 2013;11(4):407–14. doi:10.1007/s11914-013-0160-5.PubMed

106.

Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–66. doi:10.1016/S0140-6736(07)61342-7.PubMed

107.

Radford LT, Bolland MJ, Mason B, Horne A, Gamble GD, Grey A, et al. The Auckland calcium study: 5-year post-trial follow-up. Osteoporos Int. 2013. doi:10.1007/s00198-013-2526-z.PubMed

108.

McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83–90. doi:10.1038/387083a0.PubMed

109.

Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682–8. doi:10.1056/NEJMoa040933.PubMed

110.

Han DS, Chen YM, Lin SY, Chang HH, Huang TM, Chi YC, et al. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin Endocrinol. 2011;75(6):857–63. doi:10.1111/j.1365-2265.2011.04120.x.

111.

Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A. 1998;95(25):14938–43.PubMedCentralPubMed

112.

Ju CR, Chen RC. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respir Med. 2012;106(1):102–8. doi:10.1016/j.rmed.2011.07.016.PubMed

113.

Elliott B, Renshaw D, Getting S, Mackenzie R. The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol. 2012;205(3):324–40. doi:10.1111/j.1748-1716.2012.02423.x.

114.

Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, et al. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal. 2009;7:15. doi:10.1186/1478-811X-7-15.PubMedCentralPubMed

115.

Zhang ZL, He JW, Qin YJ, Hu YQ, Li M, Zhang H, et al. Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families. Osteoporos Int. 2008;19(1):39–47. doi:10.1007/s00198-007-0435-8.PubMed

116.

Hamrick MW. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol. 2003;272(1):388–91. doi:10.1002/ar.a.10044.PubMed

117.

Kellum E, Starr H, Arounleut P, Immel D, Fulzele S, Wenger K, et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 2009;44(1):17–23. doi:10.1016/j.bone.2008.08.126.PubMedCentralPubMed

118.•

Digirolamo D SV, Clemens T, Lee S-J. Systemic administration of soluble 483 activin receptors produces differential anabolic effects in muscle and bone in mice. J Bone Miner Res. 2011;1167 (Suppl.). This abstract presented at ASBMR meeting 2011 reported direct effects of activin receptor signaling in osteoblasts. Mice treated with ActRII-Fc fusion proteins showed both increases in muscle (15%–40%) and trabecular (~13%) bone over 4 weeks.

119.•

Bowser M, Herberg S, Arounleut P, Shi X, Fulzele S, Hill WD, et al. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp Gerontol. 2013;48(2):290–7. doi:10.1016/j.exger.2012.11.004. This study examined age-related differences in the expression and activity of myostatin, activin A, and follistatin in mice. Myostatin was particularly important in the impaired proliferative capacity of aged muscle and bone cells, making it an appropriate therapeutic target in treating sarcopenia-osteoporosis.PubMedCentralPubMed

120.

Koncarevic A, Cornwall-Brady M, Pullen A, Davies M, Sako D, Liu J, et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology. 2010;151(9):4289–300. doi:10.1210/en.2010-0134.PubMed

121.

Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420(6914):418–21. doi:10.1038/nature01154.PubMed

122.

Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531–43. doi:10.1016/j.cell.2010.07.011.PubMed

123.•

Chiu CS, Peekhaus N, Weber H, Adamski S, Murray EM, Zhang HZ, et al. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents. J Gerontol A Biol Sci Med Sci. 2013;68(10):1181–92. doi:10.1093/gerona/glt030. Aged mice treated with ActRIIB-Fc fusion protein showed enhanced muscle size and function after 3 days. Similar features were observed in hypogonadal male mice (ie, orchidectomized) and improvements in bone mineral density were also reported.PubMed

124.

Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010;46(4):1082–8. doi:10.1016/j.bone.2010.01.370.PubMed

125.•

Arounleut P, Bialek P, Liang LF, Upadhyay S, Fulzele S, Johnson M, et al. A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength. Exp Gerontol. 2013;48(9):898–904. doi:10.1016/j.exger.2013.06.004. Aged mice injected with a myostatin inhibitor (propeptide-Fc) showed increases in muscle mass but not bone volume. This raised questions about the precise role of myostatin signaling in bone density in aged animals.PubMedCentralPubMed

126.

Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561–71. doi:10.1002/ana.21338.PubMed

127.

Krivickas LS, Walsh R, Amato AA. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve. 2009;39(1):3–9. doi:10.1002/mus.21200.PubMed

128.•

Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416–23. doi:10.1002/mus.23539. This RCT reported increases in muscle mass and serum markers of bone formation in healthy postmenopausal women receiving a single dose of ACE-031, a soluble ActRIIB decoy receptor. Although side-effects were minor—nose bleeds, skin telangiectasia and transient drop in FSH levels—they highlight an incomplete understanding of systemic effects of activin signaling.PubMed

129.•

Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, et al. An antibody blocking Activin Type II Receptor induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34(4):606–18. doi:10.1128/MCB.01307-13. Mice injected with a novel anti ActRII antibody (BYM338) had greater increases in muscle mass than mice receiving a myostatin inhibitor alone. This agent also protected muscles from glucocorticoid-induced atrophy and has potential therapeutic implications.PubMedCentralPubMed

130.

Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481–9. doi:10.1038/nm.2513.PubMed

Titel: Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?
verfasst von: Christian M. Girgis
Nancy Mokbel
Douglas J. DiGirolamo
Publikationsdatum: 01.06.2014
Verlag: Springer US
Erschienen in: Current Osteoporosis Reports / Ausgabe 2/2014
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-014-0204-5

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Diabetes, Collagen, and Bone Quality

Ultrasound to Assess Bone Quality

Atypical Femoral Fractures, Bisphosphonates, and Mechanical Stress

Statistical Shape and Appearance Models in Osteoporosis

Clinical Considerations of Regenerative Medicine in Osteoporosis